Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
08/05/2022* -- Results Q2 2022 -- -0.44 --
08/05/2022* 16:30 EST Earnings Call Q2 2022 -- -- --
05/04/2022 -- Results Q1 2022 -0.38 -0.51 24.82%
05/04/2022 16:30 EST Earnings Call Q1 2022 -- -- --
02/22/2022 -- Results Q4 2021 -0.31 -0.37 16.87%
02/22/2022 16:30 EST Earnings Call Q4 2021 -- -- --
11/04/2021 -- Results Q3 2021 -0.21 -0.24 13.72%
11/04/2021 16:30 EST Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 08/05/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 05/04/2022
Beat/Miss Upgrade
Return Since -17.20%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
URL https://www.glaukos.com
Investor Relations URL https://investors.glaukos.com/
HQ State/Province California
Sector Healthcare
Industry Medical Devices
Equity Style Small Cap/Blend
Next Earnings Release Aug. 05, 2022 (est.)
Last Earnings Release May. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
38.92%
-25.22%
119.0%
-3.03%
38.17%
-40.95%
-11.48%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.67%
-37.42%
-66.33%
52.89%
105.8%
39.95%
27.07%
-34.74%
-18.83%
-68.18%
-52.29%
22.75%
-95.69%
-90.20%
251.9%
148.6%
-50.99%
79.59%
-42.99%
105.1%
-27.79%
21.19%
140.9%
-5.85%
10.22%
1.28%
-31.17%
-22.30%
50.00%
-16.77%
63.98%
-1.59%
-24.67%
As of May 20, 2022.

Profile

Edit
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
URL https://www.glaukos.com
Investor Relations URL https://investors.glaukos.com/
HQ State/Province California
Sector Healthcare
Industry Medical Devices
Equity Style Small Cap/Blend
Next Earnings Release Aug. 05, 2022 (est.)
Last Earnings Release May. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
WSCIX 260074.0 USD 3.46%
TFCGX 1.337M USD 2.87%
PSCH 5.792M USD 1.74%
BCSIX 93.11M USD 1.74%
ASIMX 20.32M USD 1.66%
AAMOX 55531.00 USD 1.66%
ARTJX 74.14M USD 1.38%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter GKOS Tweets